Pfizer to Share COVID-19 Vaccine Safety and Effectiveness Data
Pfizer is committed to transparently sharing data from clinical trials and real-world studies of its COVID-19 vaccine to address hesitancy.
US-based pharmaceutical company Pfizer is emphasizing its commitment to transparency regarding its COVID-19 vaccine. The company announced it will continuously publish data on the vaccine's safety and effectiveness from both clinical trials and real-world usage, in response to global vaccine hesitancy.
Pfizer, in collaboration with BioNTech, developed an mRNA-based COVID-19 vaccine. While billions worldwide have received the vaccine, some segments of the population remain hesitant. According to the company, decision-making is influenced by various factors, including social and political reasons, and a desire for more information about the vaccine's development and safety profile.
Pfizer has published its research findings in leading peer-reviewed scientific journals. Additionally, real-world effectiveness data, such as studies from Israel, have provided important information regarding the vaccine's safety and its protection against SARS-CoV-2 infection and severe disease. These data have reportedly shaped local decisions on regulatory approvals and vaccination schedules.
The company believes that clinical and real-world data are critical to understanding the vaccine's value in combating the disease. Pfizer stated that it will continue to share new research findings and analyses in the future.